Watertown, Mass., October 06, 2026 – Remix Therapeutics (Remix), Inc., a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the appointment of Michael Landsittel to its Board of Directors.   “We are delighted to welcome Michael to the Remix Board of Directors,” said […]